Emergency contraception (EC) has the potential to reduce unintended pregnancy and abortion rates. This review provides an overview of the three main methods of EC available in Australia, including the copper intrauterine device and oral ECs, levonorgestrel and ulipristal acetate, and brings together evidence from several guidelines to assist pharmacists' practices. The relative efficacy and safety of each method are discussed, together with practical recommendations regarding special considerations, including ongoing contraception, women with an elevated body mass index, drug interactions and breastfeeding. An evidence-based treatment algorithm is provided to assist in decision-making regarding EC use, with ulipristal acetate now likely to be the first-line oral EC given its superior efficacy relative to levonorgestrel, irrespective of time taken following unprotected sexual intercourse, but there are special considerations regarding its use. Pharmacists must be aware of key differences in available methods of EC and be prepared to counsel women on such to facilitate shared decision-making.
INTRODUCTION
Emergency contraception (EC) is used following an episode of unprotected sexual intercourse (UPSI) to reduce the risk of pregnancy. This may occur in the setting where no contraceptive method is being used or when contraceptive failure has occurred (e.g. broken condom, missed oral contraceptive pills). In addition, the provision of EC also represents a core component of compassionate care for victims of sexual assault. Access to safe and effective methods of contraception, including EC, comprises a key component of women's health in preventing the health and economic burdens associated with unwanted pregnancies to both individuals and society. Unwanted pregnancies remain a local, and indeed global, public health challenge. Based on South Australian statistics, it is estimated that one in three women will have an abortion during their life. Of the 5000 abortions that occur in South Australia each year, 95% are due to unwanted pregnancies. 1 There is a gap in nationally available induced abortion statistics because only two Australian states collect this data across Australia; however, the total number of abortions performed each year is estimated at 100 000. 2 The three main methods of EC available in Australia include the copper intrauterine device (IUD) and oral emergency contraceptives levonorgestrel (LNG) and ulipristal acetate (UPA). Pharmacists have played a key role in the provision of EC since the availability of LNG without a prescription from community pharmacies as a Pharmacist Only Medicine from 2004, 3 with this role further expanding through the introduction of UPA in early 2017 also as a Pharmacist Only Medicine. 4 Further, involvement of pharmacists in evidence-based EC management extends beyond the community pharmacy setting with EC commonly supplied across family planning clinics, youth health and women's health centres, sexual health, and hospital emergency medicine or outpatient clinics. Therefore, the aim of this review is to summarise available evidence regarding currently available methods of EC in Australia and provide practical recommendations regarding counselling and provision of EC in the clinical setting.
MECHANISM OF ACTION AND EFFICACY
Understanding differences in efficacy between alternative choices for EC requires knowledge of the menstrual cycle and associated fertility window, together with mechanisms of action of each type of EC. Women are at greatest risk of pregnancy when UPSI occurs in the 5 days leading up to and including the day of ovulation. 5 Menstrual cycles are typically 28 days; however, the length can vary considerably. A common misconception is that the majority of women will ovulate around day 14 of the menstrual cycle; however, more than 50% of women ovulate outside of days 12-16 of the cycle. 5, 6 Ovulation typically occurs 14 days prior to menstruation, meaning that it is possible to estimate the timing of ovulation for women who experience regular menstrual cycles by subtracting 14 days from the number of total days of their menstrual cycle. Complicating such an approach to calculating fertility windows is that menstrual cycles can be irregular and women may not be aware of their usual cycle duration. There is also a requirement for women to be able to recall the date of their last menstrual period and the exact timing of UPSI. Notwithstanding, this approach may be useful in determining a woman's risk of pregnancy following UPSI and may assist in determining the most effective EC option. For women using short-term hormonal contraceptive methods (e.g. combined oral contraceptive pill, progesterone only pill, vaginal ring) who experience possible contraceptive failure (e.g. extending hormonefree interval, missed pills), risk of pregnancy is related more to the timing at which contraceptive failure occurred. Guidelines are available to assist in the identification and resultant management of possible contraceptive failures, 7 with management advice provided in Table 1 . With respect to mechanism of action, LNG and UPA both work by delaying or inhibiting ovulation. LNG is a progesterone analogue, while UPA is a progesterone receptor modulator, possessing both agonist and antagonist properties at the progesterone receptor. Based on current evidence, neither of these medications are effective once ovulation has occurred, with their use having no effect on implantation of a fertilised egg nor on an established pregnancy. 7 While efficacy is commonly discussed relative to time elapsed since UPSI, in reality it should be considered relative to timing of ovulation. 8 That is, if ovulation has already occurred then neither oral EC will be effective. 7 Therefore, the primary determinant of likely efficacy of oral EC relates not to the time elapsed since UPSI, but to the likelihood of ovulation having already occurred relative to UPSI and EC use. The difficulty, of course, with taking this approach is that timing of ovulation is difficult to determine with suitable accuracy in the community setting, but considering efficacy from this perspective greatly assists in comparing the relative efficacy of UPA and LNG. The risk of pregnancy is considered greatest if UPSI occurs 72 h or less prior to ovulation, but sperm remains capable of fertilising an oocyte for up to 120 h, leading to a greater at-risk window. 5 Therefore, the efficacy of oral EC treatments is predicated on their ability to prevent or delay ovulation for 5 days until the risk of pregnancy is no longer present. LNG is licensed for use up to 72 h following UPSI and UPA up to 120 h following UPSI. 7 Notably, combined analysis of previous LNG studies have demonstrated continued but reduced effectiveness of LNG up to 96 h, with no effect on ovulation beyond 96 h. 9 Ulipristal acetate has been demonstrated to be more effective than LNG in preventing or delaying ovulation. When administered in the late follicular phase (i.e. follicle size ≥ 18 mm) and prior to the luteinising hormone (LH) surge, UPA delayed subsequent ovulation by at least 5 days in 100% of cycles, whereas LNG only achieved this in 25% of cycles. 8 Once the LH surge had already commenced, but before it had reached its peak, administration of UPA delayed subsequent ovulation by at least 5 days in 79% of cycles and LNG in only 14% of cycles. 8 Once the LH surge reached its peak, neither UPA nor LNG altered ovulation. 8 This means that compared to LNG, UPA continues to be effective at the time in the cycle when the risk of pregnancy is highest. An overview of relative efficacies of each oral EC according to the timing of UPSI and ovulation is provided in Figure 1 .
Such physiological data correspond to those observed in clinical studies, where UPA has been identified as being superior at all time points relative to UPSI. 10 In a pooled meta-analysis of two randomised head-to-head trials, significantly fewer women became pregnant with the use of UPA compared with LNG when used within 0-24 h (0.9% vs 2.3%; odds ratio (OR) 0.35; 95% CI, 0.11-0.93), 0-72 h (1.4% vs 2.2%; OR 0.58; 95% CI, 0.33-0.99), or 0-120 h (1.3% vs 2.2%; OR 0.55, 95% CI, 0.32-0.93). 10 That is, if used within 24 h of UPSI, when most women tend to present for EC, the risk of pregnancy is two-thirds lower for women using UPA than LNG. In contrast to oral EC, the copper IUD remains effective for up to 5 days following UPSI as it is able to prevent fertilisation and implantation. The reported efficacy of this approach is close to 100% and as such the copper IUD remains the most effective form of EC. 7 However, there are access issues which often make it difficult for copper IUDs to be used for EC.
A comparison of each of the methods of EC is provided in Table 2 .
ADVERSE EFFECTS
Both UPA and LNG are well tolerated, with a similar incidence of typically mild adverse effects. 11 The most common adverse effects reported in clinical trials include headache, nausea, dysmenorrhea (at next menses), fatigue, dizziness or abdominal pain. Women may also experience anxiety because of their fear of an unwanted pregnancy.
ONGOING CONTRACEPTION
Women should be informed that the use of LNG or UPA for EC is less effective at preventing pregnancy than other methods of contraception used regularly. Further, current use of oral EC does not protect them against the subsequent risk of pregnancy should further UPSI occur later in the cycle. There are no harms associated with repeated use of EC within the same cycle and both UPA and LNG may be used again if they have already been used earlier in the cycle. Within the same menstrual cycle, UPA can be offered again if UPA has previously been used in that cycle, and LNG can be offered if LNG has been used in the same cycle. However, LNG cannot be offered if UPA has been used in the previous 5 days of the same cycle, and UPA may be less effective if taken in the following 7 days after using LNG. 7 A study of repeated administration of UPA demonstrated the continued ability to delay ovulation for some time, but ovulation did eventually occur regardless of use.
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For women seeking ongoing contraception, hormonal contraception can be resumed or commenced immediately after taking LNG, with the caveat that a barrier method of contraception should be used until whichever chosen method becomes effective (i.e. 7 days for majority of combined oral contraceptive pills or vaginal ring, or 2 days for progesterone-only pills). 7 Recommendations are more complex following use of UPA given concerns that UPA may interact with other forms of hormonal contraceptive due to its role as a progesterone receptor modulator. 13 A recent systematic review of commencing hormonal contraception following EC use identified limited studies on which to base treatment recommendations, but did find evidence to suggest that initiation within 5 days of UPA use may negatively impact on its ability to delay ovulation, exposing women to the same risk of pregnancy faced without use of EC. 14 Therefore, if UPA is used then alternative hormonal contraception should not be commenced for 5 days, at which point an additional barrier method of contraception should be used until contraceptive cover is provided. In contrast to oral ECs, the copper IUD affords the added advantage of being able to be left in place for up to 10 years to provide ongoing contraception. 7 Despite anecdotal evidence that women believe IUDs should be reserved only for women who have 
SPECIAL POPULATIONS Contraceptive Failure
Given the role of UPA as a progesterone receptor modulator, there are theoretical concerns that recent use of hormonal contraceptive (i.e. in the few days prior to UPA use) may negatively impact on the ability of UPA to delay or prevent ovulation. While this has not been directly studied, international guidelines suggest that if a woman has taken any progestogen in the week prior to EC, the effectiveness of UPA-EC could theoretically be reduced by remaining circulating progestogen. As such, use of LNG-EC rather than UPA-EC may be considered in this situation. 7 
Women With Elevated Body Mass Index
There remains ongoing concern regarding the potential for reduced efficacy of oral EC among women with a high body mass index (BMI). [15] [16] [17] Based on data from previous randomised controlled trials, risk of pregnancy following use of either UPA or LNG was more than threefold greater for obese women compared with women with normal BMI (OR 3.60; 95% CI, 1.96-6.53). 15 The risk of pregnancy appeared greater for those exposed to LNG (OR, 4.41; 95% CI, 2.05-9.44) than UPA (OR, 2.62; 95% CI, 0.89-7.00). 15 While a gradual decline in efficacy appeared to occur as BMI increased, the greatest drop in efficacy appeared to occur beyond 70 kg for LNG and 88 kg for UPA. A recent evaluation of UPA and LNG pharmacokinetics among women of normal and obese BMI identified significant differences for LNG, but not for UPA. 18 Taken together, these findings suggest that the effectiveness of oral EC may be reduced in obese women. Given the copper IUD remains unaffected by BMI, this provides a suitable alternative in this situation. If copper IUD is not an option, UPA should be considered as first-line contraception. 15 Doubling the dose of LNG to 3 mg may also be an option but direct evidence supporting this approach is currently absent.
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Drug Interactions
Co-administration of CYP450 3A4 enzyme-inducing medications (e.g. rifampicin, phenytoin, carbamazepine, St John's wort) can lead to an increase in metabolism of both UPA and LNG, potentially leading to reduced efficacy. In situations where concerns are present regarding the potential for reduced efficacy, the copper IUD remains the preferred option. 7 Alternatively, clinical guidelines recommend increasing LNG dose to 3 mg to compensate for increased metabolism, although its effectiveness remains unproven. 7 In contrast, there are no data to support doubling the dose of UPA for EC and this approach is therefore not recommended. 7 
Breastfeeding Women
Emergency contraception is not required following UPSI occurring within the first 21 days postpartum. From 21 days onward, EC may be required if lactational amenorrhoea cannot be relied on as a form of contraception (failure rate of approximately 2%). The lactational amenorrhoea method is effective if a woman is amenorrhoeic, breastfeeding her baby on demand, both day and night and not feeding other foods or liquids regularly, and is <6 months postpartum. 7 The copper IUD is suitable to use for women who are breastfeeding and international guidelines endorse the use of LNG EC with no requirement to interrupt breastfeeding. In contrast, while some guidelines recommend expressing and discarding milk for 7 days after taking UPA in line with the manufacturer's product information, 7 this recommendation appears overly cautious.
UPA is highly protein-bound with low transfer into breast milk resulting in a relative infant dose of <1%. Peak concentration is reached within 1-3 h following administration with breast milk concentrations markedly decreasing within the first 24 h. Based on this information the Centers for Disease Control and Prevention have recommended that breast milk should only be expressed and discarded for 24 h after taking UPA. 19 In contrast to UPA, there are no concerns regarding breastfeeding following use of LNG. 7 See Figure 2 for a decision-making algorithm which will assist pharmacists in choosing between the two oral methods of EC.
BARRIERS TO EC USE
Despite significant improvements in the availability of EC over the past 15 years, no appreciable reduction has been observed with respect to unwanted pregnancies and abortions. 20 The lack of appreciable effect at the population level may relate to barriers such as lack of awareness of pregnancy risk and EC availability by women, the cost of purchasing EC, or deficiencies in knowledge regarding appropriate use of EC among healthcare professionals and women.
Interventions aimed at improving utilisation of EC have predominantly focused on removing barriers to access by making EC available in advance. While these studies have demonstrated that the likelihood of using EC was more than doubled in women given advanced supply and that timing of use relative to UPSI was shorter, no overall impact on reducing unintended pregnancies has been observed. 21 Importantly, none of these studies demonstrated negative impacts on sexual or reproductive health behaviours and outcomes. 21 While overall awareness of EC was high, poor knowledge of EC was a key factor associated with not using EC in a recent Australian study. 22 This highlights the importance of addressing widespread misperceptions about safety and mode of action, as well as misinformation about accessibility and the timeframe for use, which can hinder women's abilities to use EC. 23 Despite an absence of data from Australia, international studies have demonstrated that nine out of 10 women requesting an abortion had not used EC to try to prevent the pregnancy, despite significant improvements in awareness over time, as well as the availability of EC free of charge in countries such as Scotland. 20 These findings highlight that lack of knowledge about both when and how to use EC remain key barriers to address in future studies, as are issues related to lack of recognition of pregnancy risk following UPSI. Despite cost being noted as a barrier, little is actually known about its impact on EC use. In Scotland the LNG EC is available free of charge but no significant impacts have been observed with respect to prevention of unintended pregnancies. 24 While the copper IUD remains the most effective method of EC, there are significant barriers to access. Insertion needs to be performed by a suitably trained doctor or nurse and there also needs to be a timely clinic appointment available. In addition, the cost of a visit to the clinician on top of the cost of the device may also deter some women. With respect to oral EC, UPA may be significantly more effective than LNG but it is approximately three times the cost. This additional cost may pose a difficulty for some women, especially young women and those with low socioeconomic status. Recent studies have demonstrated the cost-effectiveness of UPA in comparison to LNG, 25 and support provision of EC free of charge.
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ADVANCED PROVISION AND COUNSELLING
Advanced provision of oral EC is encouraged for women at high risk of unintended pregnancy or those at low risk but wishing to have oral EC on hand to use if contraceptive failure occurs. Women requesting advanced supply should be provided both verbal and written counselling regarding appropriate future use and, as is the case for all women, advised to undergo a pregnancy test if they have not experienced a withdrawal bleed in the 3 weeks following EC use.
CONCLUSION
All pharmacists who see women of reproductive age should be familiar with the available methods of EC and be prepared to counsel and provide EC. The copper IUD remains the most effective method of EC and affords the additional benefit of offering cost-effective, safe, and convenient long-term contraception. Oral EC provides a convenient alternative to the copper IUD but can vary greatly in efficacy with no effect if used post-ovulation. However, because most women do not know when they ovulate, EC should be offered. While up to three times the price, UPA is superior to LNG at all stages of use and should be considered first-line oral EC in the majority of scenarios. Pharmacists should be aware of special considerations regarding the use of EC, particularly with respect to elevated BMI, drug interactions and breastfeeding. Pharmacists should provide supportive and non-judgemental care and information about specialist services such as family planning clinics where women can obtain effective ongoing contraception.
